预约演示
更新于：2025-12-12
Ipilimumab biosimilar (Cornerstone)
伊匹木单抗生物类似药(基石药业)
更新于：2025-12-12
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 143797L
当前序列信息引自: *****
Sequence Code 9060585H
当前序列信息引自: *****
关联
35
项与 伊匹木单抗生物类似药(基石药业) 相关的临床试验NCT07266025
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study
NCT07239596
An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
NCT07229625
A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer (BTC)
100 项与 伊匹木单抗生物类似药(基石药业) 相关的临床结果
登录后查看更多信息
100 项与 伊匹木单抗生物类似药(基石药业) 相关的转化医学
登录后查看更多信息
100 项与 伊匹木单抗生物类似药(基石药业) 相关的专利（医药）
登录后查看更多信息
3
项与 伊匹木单抗生物类似药(基石药业) 相关的文献（医药）2024-06-01Cancer
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study
Article
作者: Kotasek, Dusan ; Ma, Yiding ; Aghmesheh, Morteza ; Chan, Stephen L. ; Cosman, Rasha ; Zielinski, Robert ; Mant, Andrew ; Moore, Maggie ; Bishnoi, Sarwan ; Li, Peiqi ; Tse, Archie N. ; Pan, Zhaoxuan ; Yau, Thomas ; Prawira, Amy ; Su, Rila ; Li, Fei ; Eek, Richard
Abstract:
Background:
This study investigated the safety and efficacy of an anti–CTLA‐4 monoclonal antibody (CS1002) as monotherapy and in combination with an anti–PD‐1 monoclonal antibody (CS1003) in patients with advanced/metastatic solid tumors.
Methods:
The phase 1 study involved phase 1a monotherapy dose‐escalation (part 1) and phase 1b combination therapy dose escalation (part 2) and expansion (part 3). Various dosing schedules of CS1002 (0.3, 1, or 3 mg/kg every 3 weeks, or 3 mg/kg every 9 weeks) were evaluated with 200 mg CS1003 every 3 weeks in part 3.
Results:
Parts 1, 2, and 3 included a total of 13, 18, and 61 patients, respectively. No dose‐limiting toxicities or maximum tolerated doses were observed. Treatment‐related adverse events (TRAEs) were reported in 30.8%, 83.3%, and 75.0% of patients in parts 1, 2, and 3, respectively. Grade ≥3 TRAEs were experienced by 15.4%, 50.0%, and 18.3% of patients in each part. Of 61 patients evaluable for efficacy, 23 (37.7%) achieved objective responses in multiple tumor types. Higher objective response rates were observed with conventional and high‐dose CS1002 regimens (1 mg/kg every 3 weeks or 3 mg/kg every 9 weeks) compared to low‐dose CS1002 (0.3 mg/kg every 3 weeks) in microsatellite instability‐high/mismatch repair‐deficient tumors, melanoma, and hepatocellular carcinoma (50.0% vs. 58.8%, 14.3% vs. 42.9%, and 0% vs. 16.7%).
Conclusion:
CS1002, as monotherapy, and in combination with CS1003, had a manageable safety profile across a broad dosing range. Promising antitumor activities were observed in patients with immune oncology (IO)‐naive and IO‐refractory tumors across CS1002 dose levels when combined with CS1003, supporting further evaluation of this treatment combination for solid tumors.
Plain Language Summary:
CS1002 is a human immunoglobulin (Ig) G1 monoclonal antibody that blocks the interaction of CTLA‐4 with its ligands and increases T‐cell activation/proliferation. CS1003, now named nofazinlimab, is a humanized, recombinant IgG4 monoclonal antibody that blocks the interaction between human PD‐1 and its ligands.In this original article, we determined the safety profile of CS1002 as monotherapy and in combination with CS1003. Furthermore, we explored the antitumor activity of the combination in anti–programmed cell death protein (ligand)‐1 (PD‐[L]1)‐naive microsatellite instability‐high/mismatch repair‐deficient (MSI‐H/dMMR) pan tumors, and anti–PD‐(L)1‐refractory melanoma and hepatocellular carcinoma (HCC).CS1002 in combination with CS1003 had manageable safety profile across a broad dosing range and showed promising antitumor activities across CS1002 dose levels when combined with CS1003. This supports further assessment of CS1002 in combination with CS1003 for the treatment of solid tumors.
2017-01-01BMJ open4区 · 医学
Rococo study: a real-world evaluation of an over-the-counter medicine in acute cough (a multicentre, randomised, controlled study)
4区 · 医学
ArticleOA
作者: Brew, J ; Edwards, V ; Wilson, R ; Kilbourn, A ; Morice, A H ; Birring, S S
Objectives:
To investigate the efficacy and safety of CS1002, an over-the-counter cough treatment containing diphenhydramine, ammonium chloride and levomenthol in a cocoa-based demulcent.
Design:
A multicentre, randomised, parallel group, controlled, single-blinded study in participants with acute upper respiratory tract infection-associated cough.
Setting:
4 general practitioner (GP) surgeries and 14 pharmacies in the UK.
Participants:
Participants aged ≥18 years who self-referred to a GP or pharmacist with acute cough of <7 days' duration. Participant inclusion criterion was cough severity ≥60 mm on a 0–100 mm visual analogue scale (VAS). Exclusion criteria included current smokers or history of smoking within the past 12 months (including e-cigarettes). 163 participants were randomised to the study (mean participant age 38 years, 57% females).
Interventions:
Participants were randomised to CS1002 (Unicough) or simple linctus (SL), a widely used cough treatment, and treatment duration was 7 days or until resolution of cough.
Main outcome measures:
The primary analysis was intention-to-treat (157 participants) and comprised cough severity assessed using a VAS after 3 days' treatment (prespecified primary end point at day 4). Cough frequency, sleep disruption, health status (Leicester Cough Questionnaire (LCQ-acute)) and cough resolution were also assessed.
Results:
At day 4 (primary end point), the adjusted mean difference (95% CI) in cough severity VAS between CS1002 and SL was −5.9 mm (−14.4 to 2.7), p=0.18. At the end of the study (day 7) the mean difference in cough severity VAS was −4.2 mm (−12.2 to 3.9), p=0.31. CS1002 was associated with a greater reduction in cough sleep disruption (mean difference −11.6 mm (−20.6 to 2.7), p=0.01) and cough frequency (mean difference −8.1 mm (−16.2 to 0.1), p=0.05) compared with SL. There was greater improvement in LCQ-acute quality of life scores with CS1002 compared with SL: mean difference (95% CI) 1.2 (0.05 to 2.36), p=0.04 after 5 days' treatment. More participants prematurely stopped treatment due to cough improvement in the CS1002 group (24.4%) compared with SL (10.7%; p=0.02). Adverse events (AEs) were comparable between CS1002 (20.5%) and SL (27.6%) and largely related to the study indication. 6 participants (7%) in the CS1002 group reduced the dose of medication due to drowsiness/tiredness, which subsequently resolved. These events were not reported by participants as AEs.
Conclusions:
Although the primary end point was not achieved, CS1002 was associated with greater reductions in cough frequency, sleep disruption and improved health status compared with SL.
Trial registration number:
EudraCT number2014-004255-31.
Frontiers in Immunology
SHR-8068 combined with adebrelimab and bevacizumab in the treatment of refractory advanced colorectal cancer: study protocol for a single-arm, phase Ib/II study
Article
作者: Zhang, Pei ; Wang, Xin ; Wang, Jianfei ; Yang, Yu ; Li, Xiaofen ; Cao, Dan
Background:
The third-line treatment for refractory colorectal cancer (CRC) has limited efficacy. This study aimed to evaluate the safety and efficacy of SHR-8068 (an anti-CTLA-4 antibody), combined with adebrelimab (an anti-PD-L1 antibody), and bevacizumab in refractory non-microsatellite instability-high (MSI-H) or proficient mismatch repair (pMMR) CRC.
Method:
This study is a prospective, open-label, single-center phase Ib/II clinical trial. Patients with pathologically confirmed pMMR/non-MSI-H metastatic colorectal adenocarcinoma who have failed ≥2 lines prior standard systemic treatments will be enrolled (n=36). The Ib phase will evaluate two dosing regimens of SHR-8068 in combination therapy (n=9 each dosage): SHR-8068 (1 mg per kilogram, every six weeks, intravenously) or SHR-8068 (4 mg per kilogram, every twelve weeks, intravenously) combined with adebrelimab (1200 mg, every three weeks, intravenously) and bevacizumab (7.5 mg per kilogram, every three weeks, intravenously). The efficacy and adverse events (AEs) of these regimens will be assessed to determine the recommended phase II dose (RP2D) of SHR-8068. Those of RP2D group from the phase Ib will be included in the phase II. The study will go to include 18 additional patients according to the one-sample log-rank test design in the phase II. The primary endpoint of the Ib phase is safety, with secondary endpoints including the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and quality of life (QOL). The primary endpoint for phase II was PFS, with secondary endpoints including ORR, OS, DCR, safety, and QOL. Identifying biomarkers to predict the efficacy of this regimen is the exploratory study endpoint.
Discussion:
This proof-of-concept study would provide safety and efficacy signals of this novel combination treatment for the MSS CRCs in the late-line setting. And it may offer new insights on the clinical application of dual immunotherapy combined with anti-angiogenic therapy in the MSS CRC.
100 项与 伊匹木单抗生物类似药(基石药业) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期胆道癌 | 临床3期 | 中国 | 2025-11-01 | |
| 局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2025-10-22 | |
| 转移性非小细胞肺癌 | 临床3期 | 中国 | 2025-10-22 | |
| 晚期肝细胞癌 | 临床3期 | 中国 | 2024-10-28 | |
| 转移性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2024-03-01 | |
| 晚期肾细胞癌 | 临床2期 | 中国 | 2025-12-01 | |
| 肾细胞癌 | 临床2期 | 中国 | 2025-11-27 | |
| 胃食管交界处癌 | 临床2期 | 中国 | 2025-08-28 | |
| 大肠腺癌 | 临床2期 | 中国 | 2025-07-22 | |
| 宫颈癌 | 临床2期 | 中国 | 2025-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 晚期肝细胞癌 二线 | 一线 | 三线 | 101 | 艱艱衊築簾鑰壓艱鹽鹽(鹹鹽繭糧築糧簾齋衊齋) = 築選選齋獵鹹製衊襯鬱 醖簾選糧築壓網積鬱鹹 (觸鹹醖醖蓋廠蓋選鹽糧, 13.8 ~ 50.2) 更多 | 积极 | 2025-05-30 | ||
艱艱衊築簾鑰壓艱鹽鹽(鹹鹽繭糧築糧簾齋衊齋) = 構夢遞網範願選願艱艱 醖簾選糧築壓網積鬱鹹 (觸鹹醖醖蓋廠蓋選鹽糧, 33.3 ~ 61.4) 更多 | |||||||
临床1期 | 36 | 鹹膚構構鑰製觸蓋齋醖(衊鹹積鏇鑰齋顧廠觸範) = 5 (9.3%) pts had AEs leading to discontinuation of CS1002 and CS1003. 鬱醖網衊齋製製遞襯膚 (壓鬱鹽淵獵獵構淵艱襯 ) 更多 | 积极 | 2021-12-09 | |||
临床1期 | 33 | CS1003 200 mg+CS1002 0.3 mg/kg | 範鹹廠壓鹹選齋艱繭鬱(壓願繭鏇齋積淵艱夢醖) = Two (6.1%) pts experienced AEs leading to discontinuation of CS1002 and CS1003. 廠糧製範餘鏇膚遞積積 (簾簾衊衊鹹糧窪夢積顧 ) | 积极 | 2021-09-16 | ||
CS1003 200 mg+CS1002 1 mg/kg |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用